The effect of somatostatin and octreotide on intravascular oesophageal variceal pressure in patients with cirrhosis
References (7)
- et al.
The effect of different doses of a bolus injection of somatostatin combined with a slow infusion on transmural oesophageal variceal pressure in patients with cirrhosis
J Hepatol
(1994) - et al.
Octreotide infusion or emergency sclerotherapy for variceal haemorrhage
Lancet
(1993) - et al.
Somatostatin does not reduce esophageal pressure in cirrhotics
Gut
(1988)
There are more references available in the full text version of this article.
Cited by (20)
Vasopressin analogues in the treatment of hepatorenal syndrome and gastrointestinal haemorrhage
2008, Best Practice and Research: Clinical AnaesthesiologyCitation Excerpt :Although somatostatin and octreotide are not approved for treatment of variceal bleeding, they are occasionally used for this indication, particularly in countries where terlipressin is not available. However, efficacy and mechanisms of action to arrest haemorrhage and to improve the disturbed cardiovascular situation of cirrhotic patients remain unclear and uncertain for somatostatin and octreotide1,35,37–62 whereas those for terlipressin are well documented and understood1,6,9,10,14,19–36 Terlipressin has been shown to stimulate kidney function and to prolong survival time in patients with bleeding oesophageal varices1,22,31–33 while no such promising effects were observed with somatostatin or octreotide.1,56,57,59,62
Lanreotide on collateral response to endothelin-1 and vasopressin in cirrhotic rats
2006, Journal of the Chinese Medical AssociationSomatostatin and analogues in portal hypertension
2002, HepatologyPrimary prevention of variceal bleeding in people with oesophageal varices due to liver cirrhosis: a network meta-analysis
2021, Cochrane Database of Systematic Reviews
Copyright © 1995 Published by Elsevier B.V.